Novartis, Vertex outline big gene therapy plans — fueling a global boom At an old Amgen facility tucked just beyond the Rockies. In a warehouse behind a Walmart supercenter in Durham, North Carolina. On a long-time Bristol Myers Squibb site outside Princeton. The tech has emerged, and now the arms race to physically build a generation of gene therapies has begun. Novartis will spend $500 million scaling its gene therapy manufacturing efforts, Reuters reported today. That’ll put it nearly on par with Pfizer, who committed $600 million for its facilities even before any of its gene therapies have been approved. Together, 11 companies Reuters surveyed will spend $2 billion on gene therapy production. Good luck and GOD bless,